Skip to main content
. Author manuscript; available in PMC: 2010 Oct 22.
Published in final edited form as: J Immunol. 2009 Apr 1;182(7):4479–4487. doi: 10.4049/jimmunol.0713927

Table III.

Incidence and severity of EAE in PPAR-α agonist-treated mice

Incidence MCS Day 32a Mean Severityb
Gemfibrozil fed 5/5 0.8 2.4
Fenofibrate fed 6/7 0.9 2.0
EtOH fed 4/4 2.0 2.8
DMSO fed 6/6 2.5 3.5
a

Mean clinical disease score of individual animals in each treatment group at day 32 postimmunization (day 18 posttreatment).

b

Mean of the maximum clinical disease score of individual animals in each treatment group.